Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.


Press Releases

18 June 2021

BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based ..

10 June 2021

Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Go..

28 May 2021

Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 ..

Press releases (more)

Upcoming Events

June 21, 2021 at 10:00 AM CEST

SVB Leerink CybeRx Series: Vaccine Forum

June 22, 2021

Annual General Meeting

August 9, 2021 at 8:00 AM EDT

Second Quarter 2021 Earnings Call

Upcoming events (more)

Stock Quote

Jun 20, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.